Browsing Radiotherapy and Imaging by subject "Neoplasm Invasiveness"

Now showing items 1-8 of 8

    • Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. 

      Andtbacka, RHI; Agarwala, SS; Ollila, DW; Hallmeyer, S; Milhem, M; Amatruda, T; Nemunaitis, JJ; Harrington, KJ; Chen, L; Shilkrut, M; Ross, M; Kaufman, HL (2016-12)
      Background Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic ...

    • Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. 

      Gilbert, DC; Al-Saadi, R; Thway, K; Chandler, I; Berney, D; Gabe, R; Stenning, SP; Sweet, J; Huddart, R; Shipley, JM (2016-03)
      Purpose Up to 50% of patients diagnosed with stage I nonseminomatous germ cell tumors (NSGCTs) harbor occult metastases. Patients are managed by surveillance with chemotherapy at relapse or adjuvant treatment up front. ...

    • Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging. 

      Boult, JKR; Borri, M; Jury, A; Popov, S; Box, G; Perryman, L; Eccles, SA; Jones, C; Robinson, SP (2016-11)
      High grade and metastatic brain tumours exhibit considerable spatial variations in proliferation, angiogenesis, invasion, necrosis and oedema. Vascular heterogeneity arising from vascular co-option in regions of invasive ...

    • Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. 

      Huynh-Le, M-P; Fan, CC; Karunamuni, R; Thompson, WK; Martinez, ME; Eeles, RA; Kote-Jarai, Z; Muir, K; Schleutker, J; Pashayan, N; Batra, J; Grönberg, H; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Nielsen, SF; Nordestgaard, BG; Wiklund, F; Tangen, CM; Giles, GG; Wolk, A; Albanes, D; Travis, RC; Blot, WJ; Zheng, W; Sanderson, M; Stanford, JL; Mucci, LA; West, CML; Kibel, AS; Cussenot, O; Berndt, SI; Koutros, S; Sørensen, KD; Cybulski, C; Grindedal, EM; Menegaux, F; Khaw, K-T; Park, JY; Ingles, SA; Maier, C; Hamilton, RJ; Thibodeau, SN; Rosenstein, BS; Lu, Y-J; Watya, S; Vega, A; Kogevinas, M; Penney, KL; Huff, C; Teixeira, MR; Multigner, L; Leach, RJ; Cannon-Albright, L; Brenner, H; John, EM; Kaneva, R; Logothetis, CJ; Neuhausen, SL; De Ruyck, K; Pandha, H; Razack, A; Newcomb, LF; Fowke, JH; Gamulin, M; Usmani, N; Claessens, F; Gago-Dominguez, M; Townsend, PA; Bush, WS; Roobol, MJ; Parent, M-É; Hu, JJ; Mills, IG; Andreassen, OA; Dale, AM; Seibert, TM; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium (2021-02-23)
      Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS<sub>1</sub>) is associated with age at prostate cancer diagnosis ...

    • Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. 

      Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; Tan, M; Khan, A; Harris, V; McDonald, F; Lalondrelle, S; Mohammed, K; Thomas, K; Thompson, A; Kumar, P; Dearnaley, D; Horwich, A; Huddart, R (2016-04)
      Purpose Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare normal ...

    • The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011). 

      Moynihan, C; Lewis, R; Hall, E; Jones, E; Birtle, A; Huddart, R; SPARE Trial Management Group (2012-11-29)
      Background Evidence suggests that poor recruitment into clinical trials rests on a patient 'deficit' model - an inability to comprehend trial processes. Poor communication has also been cited as a possible barrier to ...

    • The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). 

      Choudhury, A; West, CM; Porta, N; Hall, E; Denley, H; Hendron, C; Lewis, R; Hussain, SA; Huddart, R; James, N (2017-02)
      Background Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from ...

    • Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. 

      Conti, DV; Darst, BF; Moss, LC; Saunders, EJ; Sheng, X; Chou, A; Schumacher, FR; Olama, AAA; Benlloch, S; Dadaev, T; Brook, MN; Sahimi, A; Hoffmann, TJ; Takahashi, A; Matsuda, K; Momozawa, Y; Fujita, M; Muir, K; Lophatananon, A; Wan, P; Le Marchand, L; Wilkens, LR; Stevens, VL; Gapstur, SM; Carter, BD; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Giles, GG; Southey, MC; MacInnis, RJ; Cybulski, C; Wokołorczyk, D; Lubiński, J; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bojesen, SE; Røder, MA; Iversen, P; Batra, J; Chambers, S; Moya, L; Horvath, L; Clements, JA; Tilley, W; Risbridger, GP; Gronberg, H; Aly, M; Szulkin, R; Eklund, M; Nordström, T; Pashayan, N; Dunning, AM; Ghoussaini, M; Travis, RC; Key, TJ; Riboli, E; Park, JY; Sellers, TA; Lin, H-Y; Albanes, D; Weinstein, SJ; Mucci, LA; Giovannucci, E; Lindstrom, S; Kraft, P; Hunter, DJ; Penney, KL; Turman, C; Tangen, CM; Goodman, PJ; Thompson, IM; Hamilton, RJ; Fleshner, NE; Finelli, A; Parent, M-É; Stanford, JL; Ostrander, EA; Geybels, MS; Koutros, S; Freeman, LEB; Stampfer, M; Wolk, A; Håkansson, N; Andriole, GL; Hoover, RN; Machiela, MJ; Sørensen, KD; Borre, M; Blot, WJ; Zheng, W; Yeboah, ED; Mensah, JE; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Wu, Y; Zhao, S-C; Sun, Z; Thibodeau, SN; McDonnell, SK; Schaid, DJ; West, CML; Burnet, N; Barnett, G; Maier, C; Schnoeller, T; Luedeke, M; Kibel, AS; Drake, BF; Cussenot, O; Cancel-Tassin, G; Menegaux, F; Truong, T; Koudou, YA; John, EM; Grindedal, EM; Maehle, L; Khaw, K-T; Ingles, SA; Stern, MC; Vega, A; Gómez-Caamaño, A; Fachal, L; Rosenstein, BS; Kerns, SL; Ostrer, H; Teixeira, MR; Paulo, P; Brandão, A; Watya, S; Lubwama, A; Bensen, JT; Fontham, ETH; Mohler, J; Taylor, JA; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Cannon-Albright, L; Teerlink, CC; Huff, CD; Strom, SS; Multigner, L; Blanchet, P; Brureau, L; Kaneva, R; Slavov, C; Mitev, V; Leach, RJ; Weaver, B; Brenner, H; Cuk, K; Holleczek, B; Saum, K-U; Klein, EA; Hsing, AW; Kittles, RA; Murphy, AB; Logothetis, CJ; Kim, J; Neuhausen, SL; Steele, L; Ding, YC; Isaacs, WB; Nemesure, B; Hennis, AJM; Carpten, J; Pandha, H; Michael, A; De Ruyck, K; De Meerleer, G; Ost, P; Xu, J; Razack, A; Lim, J; Teo, S-H; Newcomb, LF; Lin, DW; Fowke, JH; Neslund-Dudas, C; Rybicki, BA; Gamulin, M; Lessel, D; Kulis, T; Usmani, N; Singhal, S; Parliament, M; Claessens, F; Joniau, S; Van den Broeck, T; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Larkin, S; Townsend, PA; Aukim-Hastie, C; Bush, WS; Aldrich, MC; Crawford, DC; Srivastava, S; Cullen, JC; Petrovics, G; Casey, G; Roobol, MJ; Jenster, G; van Schaik, RHN; Hu, JJ; Sanderson, M; Varma, R; McKean-Cowdin, R; Torres, M; Mancuso, N; Berndt, SI; Van Den Eeden, SK; Easton, DF; Chanock, SJ; Cook, MB; Wiklund, F; Nakagawa, H; Witte, JS; Eeles, RA; Kote-Jarai, Z; Haiman, CA (2021-01-04)
      Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 ...